MCKESSON SPECIALTY HEALTH: ERLEADA (Apalutamide), the First FDA-Approved Treatment for Non-Metastatic, Castration-Resistant Prostate Cancer, Available for Order at Biologics, Inc.

Biologics, Inc., a McKesson Specialty Health oncology and complex care pharmacy services company, has been selected by the Janssen Pharmaceutical Companies of Johnson & Johnson1 to be in the limited distribution network for ERLEADA™ (apalutamide), the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer (NM-CRPC). The addition of this critical patient therapy brings the total number of oncology and supportive therapies accessible through Biologics to 115. Read More »